Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1998 1
2004 1
2005 3
2006 1
2008 3
2009 1
2010 4
2011 5
2012 5
2013 1
2014 2
2015 4
2016 5
2017 3
2018 2
2019 3
2020 6
2021 5
2022 3
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Lung Non-Small Cell Squamous Carcinoma"
Page 1
A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).
Waqar SN, Redman MW, Arnold SM, Hirsch FR, Mack PC, Schwartz LH, Gandara DR, Stinchcombe TE, Leighl NB, Ramalingam SS, Tanna SH, Raddin RS, Minichiello K, Bradley JD, Kelly K, Herbst RS, Papadimitrakopoulou VA. Waqar SN, et al. Clin Lung Cancer. 2021 May;22(3):170-177. doi: 10.1016/j.cllc.2020.09.013. Epub 2020 Oct 14. Clin Lung Cancer. 2021. PMID: 33221175 Free PMC article. Clinical Trial.
INTRODUCTION: Lung-MAP S1400K was designed to evaluate the response to telisotuzumab vedotin, an antibody-drug conjugate targeting c-MET, in patients with c-MET-positive squamous cell carcinoma (SCC). PATIENTS AND METHODS: Patients with previously trea …
INTRODUCTION: Lung-MAP S1400K was designed to evaluate the response to telisotuzumab vedotin, an antibody-drug conjugate targeting c- …
Pembrolizumab-induced agranulocytosis.
Fernández Martínez V, García-Avello Fernández-Cueto A, Valencia Soto CM, Barbadillo Villanueva S, Ochagavía Sufrategui M, Rioja Carrera M, Alonso Buznego LA, Valero Domínguez M. Fernández Martínez V, et al. J Oncol Pharm Pract. 2024 Jun;30(4):767-771. doi: 10.1177/10781552241228774. Epub 2024 Jan 30. J Oncol Pharm Pract. 2024. PMID: 38291678
CASE REPORT: We report the case of a man diagnosed with non-keratinizing squamous lung carcinoma stage IVB with programmed death-ligand 1 70% who developed agranulocytosis 10 days after a single dose of pembrolizumab as monotherapy. ...The main approach for a …
CASE REPORT: We report the case of a man diagnosed with non-keratinizing squamous lung carcinoma stage IVB with program …
Immunotherapy for Advanced Lung Cancer.
Asmar R, Rizvi NA. Asmar R, et al. Cancer J. 2015 Sep-Oct;21(5):383-91. doi: 10.1097/PPO.0000000000000151. Cancer J. 2015. PMID: 26389763 Review.
Inhibition of these checkpoints can restore and invigorate endogenous antitumor T-cell responses. The immunotherapeutic approach of checkpoint inhibition has become an important treatment option for patients with advanced non-small cell lung can …
Inhibition of these checkpoints can restore and invigorate endogenous antitumor T-cell responses. The immunotherapeutic approach of c …
Analysis of bevacizumab treatments and metastatic sites of lung cancer.
Sato H, Nagashima H, Akiyama M, Ito T, Hashimoto T, Saikawa H, Utsumi Y, Maemondo M. Sato H, et al. Cancer Treat Res Commun. 2021;26:100290. doi: 10.1016/j.ctarc.2020.100290. Epub 2020 Dec 26. Cancer Treat Res Commun. 2021. PMID: 33373900 Free article.
INTRODUCTION: Liver metastasis has not been sufficiently evaluated in lung cancer so far. We retrospectively analyzed the distant metastasis of Non-squamous non-small cell lung cancer (NSQ-NSCLC), including liver metastasis, and associati …
INTRODUCTION: Liver metastasis has not been sufficiently evaluated in lung cancer so far. We retrospectively analyzed the distant met …
Predictive Capability of PD-L1 Protein Expression for Patients With Advanced NSCLC: Any Differences Based on Histology?
Meshulami N, Tavolacci S, de Miguel-Perez D, Rolfo C, Mack PC, Hirsch FR. Meshulami N, et al. Clin Lung Cancer. 2023 Jul;24(5):401-406. doi: 10.1016/j.cllc.2023.03.014. Epub 2023 Apr 25. Clin Lung Cancer. 2023. PMID: 37208221 Review.
Lung cancer is responsible for 1.8 million annual deaths. Non-small cell lung cancers (NSCLC) represent 85% of lung cancer tumors. ...We encourage future researchers to analyze the predictability of PD-L1 biomarker expression separ …
Lung cancer is responsible for 1.8 million annual deaths. Non-small cell lung cancers (NSCLC) represent 8 …
Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02-15 study).
Auliac JB, Monnet I, Bizieux A, Greillier L, Geier M, Falchero L, Le Garff G, Lamy R, Guisier F, Ricordel C, Chouaid C, Vergnenegre A; REFRACT GFPC 02-15 investigators. Auliac JB, et al. Lung Cancer. 2021 Nov;161:122-127. doi: 10.1016/j.lungcan.2021.09.007. Epub 2021 Sep 20. Lung Cancer. 2021. PMID: 34583220 Clinical Trial.
INTRODUCTION: Advanced non-squamous non-small cell lung cancer (NsqNSCLC) progressing at the induction of a first-line of platin-based chemotherapy is a subgroup of patients with poor prognosis and few second-line treatment options. ...CO …
INTRODUCTION: Advanced non-squamous non-small cell lung cancer (NsqNSCLC) progressing at the induction of …
RAB11A Expression Is Associated With Cancer Aggressiveness Through Regulation of FGFR-Signaling in Lung Squamous Cell Carcinoma.
Gombodorj N, Azuma Y, Yokobori T, Erkhem-Ochir B, Kosaka T, Ohtaki Y, Nakazawa S, Mogi A, Yajima T, Kuwano H, Saeki H, Shirabe K. Gombodorj N, et al. Ann Surg Oncol. 2022 Oct;29(11):7149-7162. doi: 10.1245/s10434-022-11833-5. Epub 2022 May 29. Ann Surg Oncol. 2022. PMID: 35644860
BACKGROUND: Fibroblast growth factor receptor (FGFR)-signaling in lung squamous cell carcinoma (LSCC) is associated with cancer aggressiveness and poor prognosis. ...RESULTS: The study identified RAB11A as a strong predictor of poor pr …
BACKGROUND: Fibroblast growth factor receptor (FGFR)-signaling in lung squamous cell carcinoma (LSCC) is associa …
The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action.
Joerger M, Omlin A, Cerny T, Früh M. Joerger M, et al. Curr Drug Targets. 2010 Jan;11(1):37-47. doi: 10.2174/138945010790030974. Curr Drug Targets. 2010. PMID: 19839929 Review.
Pemetrexed is a newer antifolate drug that has been approved as first-line treatment for patients with advanced non-squamous, non-small cell lung cancer (NSCLC) in combination with cisplatin, and as single agent for relapsed or chemotherapy r …
Pemetrexed is a newer antifolate drug that has been approved as first-line treatment for patients with advanced non-squamous, non …
High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases.
Ge M, Zhuang Y, Zhou X, Huang R, Liang X, Zhan Q. Ge M, et al. J Neurooncol. 2017 Nov;135(2):413-418. doi: 10.1007/s11060-017-2590-x. Epub 2017 Aug 5. J Neurooncol. 2017. PMID: 28780743
Brain metastasis (BMs) of non-small cell lung cancer (NSCLC) is the most important cause of death. ...The EGFR mutation status of primary lesions was detected using the amplification refractory mutation system polymerase chain reaction. The BMs …
Brain metastasis (BMs) of non-small cell lung cancer (NSCLC) is the most important cause of death. ...The EGFR m …
IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer.
Molinier O, Besse B, Barlesi F, Audigier-Valette C, Friard S, Monnet I, Jeannin G, Mazières J, Cadranel J, Hureaux J, Hilgers W, Quoix E, Coudert B, Moro-Sibilot D, Fauchon E, Westeel V, Brun P, Langlais A, Morin F, Souquet PJ, Girard N. Molinier O, et al. ESMO Open. 2022 Feb;7(1):100353. doi: 10.1016/j.esmoop.2021.100353. Epub 2021 Dec 23. ESMO Open. 2022. PMID: 34953398 Free PMC article.
BACKGROUND: Immunotherapy using inhibitors targeting immune checkpoint programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) is currently the standard of care in patients with advanced non-small-cell lung cancer (NSCLC). ...RE …
BACKGROUND: Immunotherapy using inhibitors targeting immune checkpoint programmed cell death protein 1 (PD-1)/programmed death-ligand …
57 results